

CLEARBRIDGE HEALTH LIMITED
(the "**Company**")
(Company Registration Number: 201001436C)
(Incorporated in the Republic of Singapore)

APPLICATION FOR WAIVER FROM RULE 705(1) OF THE LISTING MANUAL

1. The Board of Directors (the "**Board**") of the Company (together with its subsidiaries, the "**Group**") wishes to announce that the Company made an application (the "**Waiver Application**") to the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 15 February 2023 to seek an extension of the deadline under Rule 705(1) of the Listing Manual Section B: Rules of Catalist of the SGX-ST (the "**Catalist Rules**"), which requires the Company to announce the financial statements of the Group (the "**FY2022 Financial Statements**") for the financial year ended 31 December 2022 ("**FY2022**"), by no later than 1 March 2023 (the "**FY2022 Deadline**").
2. Pursuant to the Waiver Application, the Company requested for a one (1) month extension of the FY2022 Deadline to announce the FY2022 Financial Statements by 1 April 2023. The reasons for the Waiver Application are set out in the paragraph 4 below.
3. The Waiver Application is currently being reviewed by the SGX-ST. The Company will make the necessary announcement in relation to the outcome of the Waiver Application in due course.
4. The Company sought the Waiver because, as of the date of the Waiver Application, the Company was not able to finalise its FY2022 Financial Statements as it was pending access by Lunadorii, Inc. ("**Lunadorii**") to the necessary financial information of two (2) of its indirect Indonesian subsidiaries, PT Tirta Medika Jaya ("**TMJ**") and PT Indo Genesis Medika ("**IGM**"). TMJ and IGM were both previously indirect subsidiaries of the Company prior to the Company's disposal of 100% of its shareholding interests in Clearbridge Medical Asia Pte. Ltd. and SAM Laboratory Pte. Ltd., which in turn held TMJ and IGM, respectively, to Lunadorii on 7 October 2022 (the "**Disposal**").

To the best of the Company's knowledge, Lunadorii has not been able to access the necessary financial information of TMJ and IGM in a timely manner and requires more time to do so because at the time of the completion of the Disposal on 7 October 2022, the management accounts of TMJ and IGM for the third quarter ended 30 September 2022 up until the date of the Disposal on 7 October 2022 were not yet available. Since the date of the Disposal on 7 October 2022, the Company has had difficulty accessing the financial information through Lunadorii due to the lack of cooperation from the staff of TMJ and IGM during the related transition process.

The Company will continue reaching out to Lunadorii to request for the necessary financial information of TMJ and IGM on a regular basis and has requested for updates regarding the status of access to the financial information.

For the reasons set out above, based on current considerations, the Company estimates that it will need a further one (1) month from the FY2022 Deadline to complete the finalisation of the Group's FY2022 Financial Statements and for the Company's auditors to substantially complete the audit before announcing the FY2022 Financial Statements.

BY ORDER OF THE BOARD

Yee Pinh Jeremy

Executive Director and Chief Executive Officer

1 March 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*